PET and SPECT Imaging and Targeted Radionuclide Therapy for Prostate and Neuroendocrine Cancers
This community focuses on the development and clinical application of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) for cancer diagnosis, alongside targeted radionuclide therapies that deliver radiation directly to tumor cells. The work primarily addresses metastatic prostate cancer and neuroendocrine tumors, utilizing specific radiotracers to visualize disease and treat resistant cases.
The research centers on the use of fluorine-18 and technetium-99m for diagnostic imaging, with a heavy emphasis on prostate-specific membrane antigen (PSMA) and somatostatin receptor targeting. Key applications include 18F-FDG PET for metabolic assessment, PSMA PET for prostate cancer staging, and peptide receptor radionuclide therapy (PRRT) using lutetium-177 for neuroendocrine tumors. The community also investigates the integration of PET with magnetic resonance imaging (MRI) and computed tomography (CT) to improve diagnostic accuracy. Clinical trials and case reports dominate the literature, focusing on patient outcomes, treatment response evaluation, and the management of metastatic disease in prostate, breast, and lung cancers.
The largest share of the community's output is found in technetium research, accounting for 27.3% of all technetium research, and 5,754 papers here. Lutetium research also shows a high concentration, representing 25.9% of all lutetium research, with 1,769 papers in this group.
The community comprises 83,028 papers, published predominantly in the European Journal of Nuclear Medicine and Molecular Imaging, Clinical Nuclear Medicine, and the Journal of Nuclear Medicine.
Recent work includes phase 3 trials for lutetium-177 PSMA-617 in metastatic prostate cancer and reviews on the molecular blueprint of targeted radionuclide therapy. The newest papers also feature studies on biparametric MRI for prostate cancer diagnosis and trial designs for patients with metastatic castration-sensitive prostate cancer.